Avadel Pharmaceuticals/$AVDL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Avadel Pharmaceuticals
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Ticker
$AVDL
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
188
ISIN
IE00BDGMC594
Website
AVDL Metrics
BasicAdvanced
$854M
-
-$0.27
-
-
Price and volume
Market cap
$854M
52-week high
$17.30
52-week low
$6.38
Average daily volume
1.5M
Financial strength
Current ratio
2.734
Quick ratio
2.122
Long term debt to equity
50.907
Total debt to equity
51.86
Interest coverage (TTM)
-1.85%
Profitability
EBITDA (TTM)
-16.4
Gross margin (TTM)
90.06%
Net profit margin (TTM)
-13.58%
Operating margin (TTM)
-9.96%
Effective tax rate (TTM)
0.98%
Revenue per employee (TTM)
$1,030,000
Management effectiveness
Return on assets (TTM)
-7.21%
Return on equity (TTM)
-34.65%
Valuation
Price to revenue (TTM)
4.366
Price to book
11.49
Price to tangible book (TTM)
14.87
Price to free cash flow (TTM)
-33.379
Free cash flow yield (TTM)
-3.00%
Free cash flow per share (TTM)
-26.39%
Growth
Revenue change (TTM)
252.64%
Earnings per share change (TTM)
-84.81%
10-year revenue growth (CAGR)
16.36%
3-year earnings per share growth (CAGR)
-43.76%
10-year earnings per share growth (CAGR)
-13.36%
What the Analysts think about AVDL
Analyst ratings (Buy, Hold, Sell) for Avadel Pharmaceuticals stock.
Bulls say / Bears say
Avadel Pharmaceuticals' inclusion in the Russell 3000® Index in July 2024 enhances its visibility among investors, potentially attracting more institutional interest. (biospace.com)
The FDA's approval of LUMRYZ for pediatric narcolepsy patients aged seven and older in October 2024 expands the drug's market potential, contributing to increased revenue streams. (tradingview.com)
Analysts have set a consensus 12-month price target of $18.00 for Avadel Pharmaceuticals, indicating potential upside from its current trading price. (reuters.com)
Avadel Pharmaceuticals reported a net loss of $48.832 million in its latest annual report, highlighting ongoing financial challenges despite increased revenue. (tradingview.com)
The company faces competition from generic versions of sodium oxybate, such as those launched by Hikma Pharmaceuticals and Amneal Pharmaceuticals in 2023, which could impact LUMRYZ's market share. (tradingview.com)
Avadel Pharmaceuticals has a relatively high level of debt, with debt exceeding 40% of its equity, which may pose financial risks and limit operational flexibility. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AVDL Financial Performance
Revenues and expenses
AVDL Earnings Performance
Company profitability
AVDL News
AllArticlesVideos
ASL pushes for board shakeup at Avadel over handling of sleep drug rollout
Reuters·2 days ago
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders
Business Wire·2 days ago
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avadel Pharmaceuticals stock?
Avadel Pharmaceuticals (AVDL) has a market cap of $854M as of July 02, 2025.
What is the P/E ratio for Avadel Pharmaceuticals stock?
The price to earnings (P/E) ratio for Avadel Pharmaceuticals (AVDL) stock is 0 as of July 02, 2025.
Does Avadel Pharmaceuticals stock pay dividends?
No, Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders as of July 02, 2025.
When is the next Avadel Pharmaceuticals dividend payment date?
Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders.
What is the beta indicator for Avadel Pharmaceuticals?
Avadel Pharmaceuticals (AVDL) does not currently have a Beta indicator.